ARCHIVES

Second-Generation CML Drugs Show Promise For Frontline

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

Decision To Screen For Prostate Cancer Should Include Patients, ACS Panel Says

March 21, 1997

LAK –IL-2 Studies Continue, Moertel Editorial Blasted

March 13, 1987

Is OMB Paying More Attention To Bypass Budget? NCI Awaits FY 1984 Figure

November 26, 1982

Clinical Trial System Inefficient, UPCI Director Tells Senate

June 7, 2002

Public Forum On NRSA Tuition Policies

April 14, 1995